Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 90 months
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 86 months
Number of Participants with Detectable Anti-Drug Antibodies (ADAs)
Timeframe: Up to approximately 88 months
Laboratory parameters (Hematology): Concentration of Platelets and Hemoglobin
Timeframe: Up to approximately 88 months
Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT)
Timeframe: Up to approximately 86 months
Change From Baseline in Body Weight
Timeframe: Baseline and up to approximately 86 months
Change From Baseline in Blood Pressure
Timeframe: Baseline and up to approximately 86 months
Change From Baseline in Electrocardiogram (ECG)
Timeframe: Baseline and up to approximately 86 months